Key Takeaways
|
|---|
Every delayed launch, every missed market window, every campaign that goes live two months late: most trace back to slow MLR operations as much as to slow reviewers. The promotional review process is non-negotiable in pharma. What is negotiable is how efficiently the team structures the work around it, including who owns what, how materials move through stages, and whether the supporting tools accelerate or slow that motion. Pharma companies that have optimized their review workflows have documented up to 57% reductions in review cycle times. The variable that most often separates them from peers is operational design rather than reviewer expertise.
This post breaks down what high-functioning ops teams actually do, which KPIs matter, how dashboards surface the right signals, and where workflow automation delivers real efficiency gains. Whether you manage review cycle management for a single brand team or across a global portfolio, these are the operational levers that determine how fast compliant content reaches market.
What Does MLR Operations Actually Own?
The term 'MLR operations' gets applied loosely. Sometimes it means the review committee itself, sometimes the tools and systems team, sometimes a standalone ops function embedded in marketing. For the purposes of this discussion, the function refers to the people and processes responsible for keeping promotional review cycles moving: coordinating submissions, managing routing workflows, tracking status, enforcing timelines, and maintaining process consistency across brands and markets.
Understanding that scope matters because it defines who is accountable for cycle efficiency. Reviewers (medical, legal, regulatory) are accountable for review quality. The ops function is accountable for review velocity and process integrity.
Core Responsibilities of the Ops Function
The function typically owns four categories of work. First, it governs workflow design: defining submission standards, routing logic, stage gates, and internal timeline targets at each review step. Second, it owns coordination: ensuring the right materials reach the right reviewers at the right time, with all required supporting documentation. Third, it manages visibility: maintaining status dashboards, escalating stalled items, and reporting cycle metrics to leadership. Fourth, it drives continuous improvement: analyzing where cycles break down and working cross-functionally to address root causes.
On the agency side, promotional review operations often map onto similar responsibilities. Project managers and ops leads coordinate asset submissions to pharma clients, manage revision cycles, and ensure materials are packaged correctly before they enter the client's internal review queue. In both contexts, the job is the same: reduce friction in the path between draft and approval.
Who Owns What: A Cross-Functional Accountability Map
Confusion about ownership is one of the most common drivers of cycle delays. When no one is explicitly responsible for moving a stalled asset, it sits. The table below captures the primary accountability of each stakeholder group within a standard MLR operations workflow.
Role | Primary Accountability | Key Handoff |
|---|---|---|
Marketing / Brand Team | Asset creation, claim sourcing, submission packaging | Submits to MLR ops with full references and annotations |
MLR Ops Coordinator | Routing, timeline tracking, status visibility, escalation | Routes packaged submission to appropriate reviewer queue |
Medical Reviewer | Clinical accuracy, claims substantiation, fair balance | Returns comments or approval to ops queue |
Legal Reviewer | Liability exposure, IP, disclaimers, consent language | Returns comments or approval to ops queue |
Regulatory Reviewer | FDA/EMA compliance, channel rules, label alignment | Issues final regulatory sign-off or revision request |
Agency Partner | Content production, reference annotation, version control | Delivers formatted submission-ready package to pharma MLR ops |
What KPIs Should MLR Operations Teams Be Tracking?
Most pharma organizations track workflow management performance loosely. Cycle time is usually the headline number, but it tells an incomplete story without the supporting metrics that reveal where time is actually being lost. A mature ops function should be monitoring the full set of operational indicators below.
Measuring the right KPIs is foundational to improvement. Without a clear baseline on where materials spend their time, every process change is a guess.
The Core KPI Set
These metrics cover the full content lifecycle from submission to approval:
End-to-end cycle time. Total elapsed time from initial submission to final approval. This is the headline metric but must be disaggregated to be actionable.
Time in queue vs. active review time. The gap between when an asset is submitted and when a reviewer opens it is often where cycle time is lost, not in the review itself.
First-pass approval rate. The percentage of assets that clear initial review without revision requests. A low rate signals upstream quality problems in content preparation, claims sourcing, or annotation completeness.
Revision cycle count. How many back-and-forth rounds the average asset requires before approval. High revision counts often point to ambiguous submission standards or inconsistent reviewer expectations.
Review throughput. Total assets cleared per week or month, segmented by brand, reviewer, or asset type. Throughput declines often signal reviewer capacity constraints before they become launch-blocking delays.
Building a Review Operations Dashboard
KPI tracking is only as useful as the visibility layer on top of it. A well-designed review cycle management dashboard should answer three questions at a glance: What is currently in flight? Where are assets stalled? What is trending week-over-week? Rolling views of cycle time by brand and asset type, combined with queue depth and stage-level timeline adherence, give ops leaders the signal they need to intervene before delays compound into launch problems.
The most effective dashboards distinguish between what is in reviewers' hands and what is waiting to get there. If average time-in-queue is higher than average active review time, the process fix lies in routing and coordination, not in asking reviewers to work faster.
5 Workflow Automation Opportunities in Pharma MLR Operations
Automation in pharma review environments is not about replacing the human judgment at the center of every review. It is about eliminating the manual coordination work that surrounds it: the routing emails, the status check-ins, the spreadsheet updates, the reference annotation from scratch. Here are five areas where workflow automation delivers the clearest operational returns.
Pre-submission quality checks. AI-assisted review can scan content against approved claims libraries, fair balance requirements, and regulatory standards before materials ever enter the formal review queue. Catching issues upstream reduces first-pass failure rates and eliminates the most time-consuming revision cycles.
Automated routing and role-based assignment. Rule-based routing ensures that each asset reaches the correct reviewers in the correct sequence, without requiring manual coordination by an ops team member. This reduces queue time and eliminates routing errors that send materials to the wrong person or in the wrong order.
Timeline enforcement and escalation triggers. Automated reminders and escalation workflows ensure that no asset sits idle without accountability. When a review stage approaches the team's internal turnaround threshold, the system surfaces the issue rather than requiring an ops coordinator to manually track and chase it.
Claims library synchronization. Maintaining an accurate, searchable claims library manually is one of the highest-effort, lowest-leverage tasks in promotional review operations. Automated claims extraction and synchronization keeps the library current without requiring dedicated staff time, while also reducing the risk of submitting outdated or unapproved claim language.
Audit trail and version control automation. Automated documentation of every review action, comment, and approval creates a defensible audit trail without burdening ops staff with manual logging.
What Does a Mature MLR Workflow Management System Look Like?
The gap between early-stage and mature MLR workflow management is significant, and it is not primarily a technology gap. It is a governance gap. Organizations that have moved beyond reactive review cycles share several structural characteristics that are worth modeling.
A maturity analysis of pharma MLR functions identifies a consistent progression: organizations typically move from manual, email-driven setups to workflow tools with partial automation, to integrated AI-assisted systems with unified KPIs, and ultimately to predictive compliance and dynamic orchestration. Each level requires clear ownership, defined KPIs, and active change management in addition to new technology, and each unlocks measurable gains in throughput, quality, and audit readiness.
Structural Markers of a Mature Function
High-functioning ops teams share these characteristics:
Documented submission standards that marketing and agency partners follow consistently, reducing the number of incomplete or incorrectly packaged submissions that arrive in the review queue
Defined turnaround targets at each stage of review, not only at the end-to-end level, with clear escalation paths when timelines are missed
A centralized claims library that is actively maintained and searchable, eliminating redundant claims substantiation work
Regular cadence of ops review meetings to analyze KPI trends, identify recurring bottlenecks, and close the loop on process changes
Cross-functional stakeholder alignment on shared objectives, including a shared understanding of how cycle efficiency connects to commercial performance, beyond reviewer compliance alone
MLR Operations Maturity Level | Characteristics | Primary Bottleneck |
|---|---|---|
Level 1: Manual | Email-driven routing, spreadsheet tracking, ad hoc timelines | No visibility; assets stall silently |
Level 2: Workflow Tools | Defined stages in existing review platforms; partial timeline enforcement | Inconsistent adoption; routing errors persist |
Level 3: AI-Assisted | Pre-submission checks, automated routing, claims library, real-time dashboards | Change management; integrating AI output into existing reviewer habits |
Level 4: Predictive | AI surfaces compliance risk before submission; portfolio-level orchestration; unified global KPIs | Governance complexity at scale |
Most mid-size pharma organizations and their agency partners are operating at Level 2, with elements of Level 3 emerging. Reaching Level 3 consistently, where operations are genuinely AI-assisted and dashboards reflect live workflow data, requires the right technology embedded in the right workflow, with governance that ensures teams actually use it.
FAQ
What is the role of MLR operations in pharma marketing?
MLR operations is the function responsible for managing the efficiency and integrity of the promotional review process. While medical, legal, and regulatory reviewers assess content quality and compliance, the ops function owns workflow design, routing logic, timeline enforcement, and performance tracking. Without dedicated ops ownership, review cycles become ad hoc and bottlenecks become invisible.
What KPIs should we be tracking for MLR workflow management?
The most operationally useful MLR workflow management KPIs are: end-to-end cycle time, time in queue versus active review time, first-pass approval rate, revision cycle count, review throughput by brand or asset type, and stage-level timeline adherence. Tracking these together gives a layered view of where assets are moving efficiently and where they are stalling.
How do you reduce revision cycles in promotional review operations?
Revision cycles are most commonly driven by incomplete submissions, ambiguous claim annotations, or inconsistent reviewer expectations. The most effective interventions are upstream: AI-assisted pre-submission checks that catch common issues before formal review begins, standardized submission processes, and a well-maintained claims library that provides reviewers with the context they need to assess materials efficiently.
What should we look for in an AI tool for MLR operations?
The most important criteria are: breadth of coverage across all MLR review categories (rather than one or two), flexibility in deployment so teams are not forced to abandon existing workflows, and a low-friction implementation path that accepts materials in their current formats. AI tools that require extensive data transformation value tend to see low adoption rates, which undermines any efficiency gains the technology could otherwise deliver.
Build the Operational Foundation Your Review Cycles Require
Promotional review in pharma is never going to be simple. The regulatory stakes are too high and the stakeholder complexity too real. But the gap between a 10-week review cycle and a 2-week review cycle is almost never a function of how hard reviewers work. It is a function of how well the review cycle management infrastructure around them is designed. Clear ownership, the right KPIs, a dashboard that surfaces problems before they become delays, and workflow automation embedded in the tools teams already use: these are the operational levers that determine whether your content reaches market on schedule.
If your team is ready to move from manual review to AI-assisted MLR, Revisto was purpose-built for this problem. With flexible deployment options, including Revisto Studio for teams that want a dedicated AI workspace, and an implementation path that requires no data transformation, Revisto integrates into your existing review workflow rather than disrupting it. Reach out to the Revisto team to see what it looks like in your environment.